Table 2.
Sex-adjusted and multivariable logistic regression for correlations between the TKV ≥1000 ml and risk factors (entire cohort, N = 129)
| Variables A. Sex-adjusted logistic regression analyses |
Model for PKD1 truncating mutation (R2 = 0.08, AUC = 0.68) |
Model for PKD1 splicing/frameshift mutation (R2 = 0.10, AUC = 0.70) |
Model for PKD1 nonsense mutation (R2 = 0.07, AUC = 0.66) |
Model for PKD1 substitution (R2 = 0.07, AUC = 0.66) |
||||
|---|---|---|---|---|---|---|---|---|
| Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | |
| Men (vs. women) | 3.59 (1.67–7.71) | 0.0001a | 3.56 (1.64–7.76) | 0.0014a | 3.65 (1.71–7.83) | 0.0008a | 3.59 (1.67–7.69) | 0.0010a |
| PKD1 truncating mutation (vs. no) | 1.61 (0.77–3.36) | 0.2057 | — | — | — | — | — | — |
| PKD1 splicing mutation or frameshift mutation (vs. no) | — | — | 3.09 (1.23–7.76) | 0.0165a | — | — | — | — |
| PKD1 nonsense mutation (vs. no) | — | — | — | — | 0.85 (0.35–2.03) | 0.7115 | — | — |
| PKD1 substitution (vs. no) | — | — | — | — | — | — | 0.74 (0.31–1.79) | 0.5048 |
| B. Multivariable logistic regression analyses | Model for PKD1 truncating mutation (R2 = 0.15, AUC = 0.75) |
Model for PKD1 splicing/frameshift mutation (R2 = 0.17, AUC = 0.77) |
Model for PKD1 nonsense mutation (R2 = 0.15, AUC = 0.76) |
Model for PKD1 substitution (R2 = 0.15, AUC = 0.75) |
||||
|---|---|---|---|---|---|---|---|---|
| Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | Odds ratio (95% CI) | P value | |
| Men (vs. women) | 1.84 (0.76–4.45) | 0.1771 | 1.88 (0.77–4.61) | 0.1685 | 1.82 (0.75–4.40) | 0.1826 | 1.82 (0.75–4.39) | 0.1843 |
| Hypertension (vs. no) | 3.01 (1.29–7.00) | 0.0107a | 3.00 (1.27–7.09) | 0.0122a | 3.21 (1.37–7.53) | 0.0074a | 3.09 (1.33–7.18) | 0.0087a |
| Hyperuricemia (vs. no) | 1.99 (0.73–5.41) | 0.1777 | 1.91 (0.70–5.26) | 0.2081 | 2.14 (0.79–5.77) | 0.1346 | 2.01 (0.74–5.45) | 0.1713 |
| Low high-density lipoprotein cholesterol (vs. no) | 1.82 (0.49–6.71) | 0.3675 | 1.69 (0.45–6.32) | 0.4386 | 1.68 (0.46–6.15) | 0.4338 | 1.83 (0.50–6.75) | 0.3634 |
| PKD1 truncating mutation (vs. no) | 1.36 (0.62–2.99) | 0.4377 | — | — | — | — | — | — |
| PKD1 splicing mutation or frameshift mutation (vs. no) | — | — | 2.69 (1.02–7.10) | 0.0454a | — | — | — | — |
| PKD1 nonsense mutation (vs. no) | — | — | — | — | 0.69 (0.27–1.76) | 0.4308 | — | — |
| PKD1 substitution (vs. no) | — | — | — | — | — | — | 0.79 (0.31–2.03) | 0.6262 |
AUC, area under the receiver operating characteristic curve; PKD, polycystic kidney disease; R2, McFadden’s pseudo-R-squared; TKV, total kidney volume.
Each mutation type, hypertension, hyperuricemia, and low high-density lipoprotein cholesterol were included in the multivariable model.
a
P < 0.05.